Short Report: Can We Use a Lower Dose of Liposomal Amphotericin B for the Treatment of Mucosal American Leishmaniasis?

Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPAMATO, Valdir S.TUON, Felipe F.CAMARGO, Raphael A.SOUZA, Regina M.SANTOS, Carolina R.NICODEMO, Antonio C.2017-11-272017-11-272011AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, v.85, n.5, p.818-819, 20110002-9637https://observatorio.fm.usp.br/handle/OPI/22787Liposomal amphotericin B has been used as an alternative treatment of mucosal leishmaniasis, but the optimal dose is not established. We retrospectively reviewed the clinical outcome of eight patients with mucosal leishmaniasis treated with liposomal amphotericin B. The mean total dose was 35 mg/kg (range 24-50 mg/kg), which resulted in the healing of all the lesions in all patients and no recurrences were observed during the follow-up period (mean 25 months; range 7-40 months).engrestrictedAccessvisceral leishmaniasisShort Report: Can We Use a Lower Dose of Liposomal Amphotericin B for the Treatment of Mucosal American Leishmaniasis?articleCopyright AMER SOC TROP MED & HYGIENE10.4269/ajtmh.2011.11-0287Public, Environmental & Occupational HealthTropical Medicine